You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Urbanscape: Single Shot Multi-Task 3D Reconstruction

    SBC: DZYNE TECHNOLOGIES, LLC            Topic: DTRA18B001

    Hazard assessment tools that model the transport and dispersion of Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) materials through urban areas are only as good as the 3D models that inform the physics model. Maintaining accurate, up-to-date 3D models of urban areas is challenging. Even in the commercial world, urban construction and demolition may result in the models created a ...

    STTR Phase II 2020 Department of DefenseDefense Threat Reduction Agency
  2. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD RESEARCH CORPORATION            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens, whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial and alphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable an ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  3. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terrible morbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditional vaccines have contributed greatly to public health, they have some limitations especially in the context of operati ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  4. Discrete 3-D Electronics for Mobile Radiation Detection Systems

    SBC: RADIATION DETECTION TECHNOLOGIES, INC.            Topic: DTRA18B002

    Phase II will utilize knowledge gained from phase I work to develop and execute a manufacturing process suitable for producing quantities of 3-D printed discrete circuits for radiation detection systems.  The goal is to support mobile radiation detection system requirements for high voltage, analog amplification, and MCA functionality to produce differential pulse height spectra in time sequence. ...

    STTR Phase II 2020 Department of DefenseDefense Threat Reduction Agency
  5. Circulating Diagnostic Markers of Infectious Disease

    SBC: PATHOVACS INCORPORATED            Topic: CBD18A001

    Assays for accurate diagnosis of early stages of infection with biothreat agents, on the day of infection or within a few days of infection, will find wide use in both civilian and military applications These diagnostic assays, which are anticipated to be highly specific and sensitive, will add to the repertoire of tools of hospitals and clinics that serve our armed forces personnel deployed on th ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  6. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Through this STTR contract, we propose to evaluate the efficacy of our vaccine, FlowVax Marburg, in nonhuman primates (NHPs). This will be achieved through four Tasks. In Task 1, we will manufacture the vaccine in a quantity sufficient for the animal studies. In Task 2, we will perform MHC genotyping on a representative population of NHPs and, based on results, select a set of MHC-matched NHPs for ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government